SCHEMBL5147186

SCHEMBL5147186

CC(O)Cc1ccc(C#C[Si](C)(C)C)s1

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.35
ALOX5 P09917 3/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22769287 0.79 DPP4 (0.45) DPP4
SCHEMBL5146975 0.77 HDAC8 (0.37) DPP4
SCHEMBL361289 0.75 DPP4 (0.32) DPP4
SCHEMBL4915211 0.71
SCHEMBL28176135 0.69 ACACB (0.39)
SCHEMBL3685554 0.69 KCNH2 (0.36)
SCHEMBL3180472 0.69 KCNH2 (0.36)
SCHEMBL14849717 0.69 DPP4 (0.35) DPP4
SCHEMBL1173602 0.69 PRMT6 (0.33)
SCHEMBL5432901 0.69 PRMT6 (0.47) EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562588-A4 USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS MERCK & CO INC (US) 2007-10-31 EP disclosed
EP-1562588-A2 USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS Merck & Co., Inc. (US) 2005-08-17 EP disclosed
EP-1436290-A1 ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITOR Merck Frosst Canada & Co. (CA) 2004-07-14 EP disclosed
WO-2004045508-A2 USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS MERCK & CO., INC. (US) 2004-06-03 WO disclosed
WO-2003018579-A1 ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-03-06 WO disclosed